GenoME Funding Round

3/3/2023

Venture Equity

$1,680,000

Series A

The pre-Series A capital will help the company further develop its OvaME product, which improves on the status quo of CA125 blood tests that have been shown to provide less than accurate ovarian cancer test results, by measuring levels of patented DNA methylation markers in a blood sample, incorporating the high sensitivity of droplet digital PCR. Additionally, the startup plans to file for EU regulatory approval and expand its regulatory approach to the UK and North America.

Private & Independent

EdTech

97 Lisburn Road Belfast
Northern Ireland, BT9 7AY
UK

GenoME Diagnostics Ltd is a spin-out of Queen's University Belfast. GenoME Diagnostics was founded as a result of a decade of scientific research at the prestigious Patrick G Johnston Centre for Cancer Research. We are currently developing our lead product -- OvaME, a blood test for earlier and more accurate diagnosis of ovarian cancer. Our mission is to improve the ovarian cancer diagnostic pathway. Our pipeline utilises cutting-edge technology to provide user-friendly and cost-effective diagnostics. It can be applied to biomarker discovery and development in a wide range of diseases and applications.